|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
06160 BEONE MEDICINES
Nominal 
187.800 -0.400 (-0.213%) | 2024/12 - Final USD(K$) | %Chg (Compare to Final) | 2023/12 USD(K$) | 2022/12 USD(K$) | 2021/12 USD(K$) | 2020/12 USD(K$) | |
| Turnover | 3,810,241 | 54.965% | 2,458,779 | 1,415,921 | 1,176,283 | 308,874 |
| Cost of Sales | (594,089) | 56.372% | (379,920) | (286,475) | -- | -- |
| Gross Profit | 3,216,152 | 54.708% | 2,078,859 | 1,129,446 | -- | -- |
| 2024/12 - Final USD(K$) | %Chg (Compare to Final) | 2023/12 USD(K$) | 2022/12 USD(K$) | 2021/12 USD(K$) | 2020/12 USD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | (12,638) | -- | 307,891 | (223,852) | 15,904 | 37,490 | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (533,001) | -35.459% | (825,836) | (1,961,037) | (1,438,588) | (1,618,194) | |
| Taxation | (111,785) | 100.073% | (55,872) | (42,778) | (19,228) | 17,671 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 3,617 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (644,786) | -26.871% | (881,708) | (2,003,815) | (1,457,816) | (1,596,906) | |
| 2024/12 - Final USD(K$) | %Chg (Compare to Final) | 2023/12 USD(K$) | 2022/12 USD(K$) | 2021/12 USD(K$) | 2020/12 USD(K$) | |
| Net Finance Costs / (Income) | (117,477) | -22.906% | (152,382) | (126,714) | 2,229 | (22,350) |
| Depreciation & Amortisation | 171,762 | 95.908% | 87,675 | 66,278 | 46,457 | 50,060 |
| Directors' Emoluments | 27,473 | 7.674% | 25,515 | 24,838 | 26,142 | 25,290 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -47.000 | -27.692% | -65.000 | -149.000 | -121.000 | -147.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | (0.103) | -- | (0.853) | (1.116) | (1.077) | (1.183) |
| NBV per share ($) | 2.406 | -- | 2.611 | 3.243 | 4.606 | 3.264 |
| Remarks: | Real time quote last updated: 28/10/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K$) | USD 95,590 |
| %Change | -- |
| EPS / (LPS) | USD 0.070 |
| NBV Per Share ($) | USD 2.449 |